ArticleWorld journal of surgery2026
Dynamic Evolution of HER2 Expression Following Neoadjuvant Therapy and Its Association With Treatment Response and Prognosis in Breast Cancer: A Large-Scale Retrospective Study.
Article in World journal of surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundHER2 status in heterogeneous breast cancer (BC) can change dynamically during treatment, and is associated with prognosis and clinical decisions. Understanding the patterns of these changes may inform risk stratification and treatment planning.
methodsThis retrospective study analyzed 3748 BC patients with residual disease following neoadjuvant therapy (NAT) (2015-2021). HER2 status was assessed according to ASCO/CAP guidelines and pathological response by the Miller-Payne grading system. Multinomial logistic regression and Cox models identified factors linked to HER2 conversion and its association with treatment response and survival outcomes.
resultsHER2 status post-NAT showed 22.9% overall discordance (11.2% loss; 11.7% gain), predominantly between HER2-0 and HER2-low. Multivariate analysis revealed that age ≥ 50 years was associated with reduced likelihood of HER2 gain (adjusted OR 0.69, p < 0.001), whereas HR-positivity was associated with increased likelihood (adjusted OR 1.35, p = 0.027). Intratumoral calcification (adjusted OR 0.75, p = 0.006) and clinical stage III (adjusted OR 0.77, p = 0.016) were associated with decreased risk of HER2 loss. Conversion from HER2-0 to HER2-low status was significantly associated with poorer pathological response (adjusted OR 0.47, p = 0.011) and independently predicted inferior RFS (adjusted HR 1.33, p = 0.009) and OS (adjusted HR 1.40, p = 0.032). The adverse prognostic impact of HER2 evolution was particularly pronounced in HR-positive patients (interaction p < 0.05).
conclusionDynamic alterations in HER2 status following NAT are significantly associated with treatment response and survival outcomes. For patients without pathological complete response, reassessment of HER2 status after NAT may help identify those with distinct prognostic profiles and who are potential candidates for emerging antibody-drug conjugate therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.